应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
MTSR Metsera Inc.
休市中 06-12 16:00:00 EDT
70.50
+0.00
0.00%
最高
70.50
最低
70.50
成交量
0.00
今开
70.50
昨收
70.50
日振幅
0.00%
总市值
74.29亿
流通市值
45.48亿
总股本
1.05亿
成交额
0.00
换手率
0.00%
流通股本
6,451万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
Metsera百亿并购之后:派格生物的估值天花板在哪里?
美港探案 · 03-12
Metsera百亿并购之后:派格生物的估值天花板在哪里?
Metsera(MTSR.US)获坎托菲茨杰拉德公司首次覆盖,给予增持评级。
金融界 · 2025-02-25
Metsera(MTSR.US)获坎托菲茨杰拉德公司首次覆盖,给予增持评级。
热闹的“2025减肥药第一股”,不属于我们
蓝鲸财经 · 2025-02-13
热闹的“2025减肥药第一股”,不属于我们
Metsera纳斯达克上市:首日大涨47%,市值28亿美元,主治肥胖症
雷递网 · 2025-02-01
Metsera纳斯达克上市:首日大涨47%,市值28亿美元,主治肥胖症
异动解读 | Metsera在纳斯达克成功上市 筹资2.75亿美元 股价盘中大涨41.67%
异动解读 · 2025-02-01
异动解读 | Metsera在纳斯达克成功上市 筹资2.75亿美元 股价盘中大涨41.67%
Metsera今晚纳斯达克上市:发行价18美元 募资2.75亿美元
雷递网 · 2025-01-31
Metsera今晚纳斯达克上市:发行价18美元 募资2.75亿美元
医疗IPO活跃,今晚Metsera和Maze上市
智通财经 · 2025-01-31
医疗IPO活跃,今晚Metsera和Maze上市
加载更多
公司概况
公司名称:
Metsera Inc.
所属市场:
NASDAQ
上市日期:
--
主营业务:
Metsera, Inc.最初于2022年6月29日根据特拉华州法律注册成立。该公司是一家临床阶段的生物技术公司,开发下一代注射和口服营养刺激激素,或NUSH,类似物肽,用于治疗肥胖、超重和相关疾病。
发行价格:
--
{"stockData":{"symbol":"MTSR","market":"US","secType":"STK","nameCN":"Metsera Inc.","latestPrice":70.5,"timestamp":1781294400000,"preClose":70.5,"halted":0,"volume":0,"delay":0,"changeRate":0,"floatShares":64513712,"shares":105376189,"eps":-5.892395,"marketStatus":"休市中","change":0,"latestTime":"06-12 16:00:00 EDT","open":70.5,"high":70.5,"low":70.5,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-5.892395,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1781510400000},"marketStatusCode":7,"adr":0,"listingDate":1738299600000,"exchange":"NASDAQ","adjPreClose":70.5,"volumeRatio":0,"impliedVol":0.3139,"impliedVolPercentile":0.2281},"requestUrl":"/m/hq/s/MTSR","defaultTab":"news","newsList":[{"id":"2619167085","title":"Metsera百亿并购之后:派格生物的估值天花板在哪里?","url":"https://stock-news.laohu8.com/highlight/detail?id=2619167085","media":"美港探案","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619167085?lang=zh_cn&edition=full","pubTime":"2026-03-12 14:12","pubTimestamp":1773295920,"startTime":"0","endTime":"0","summary":"反观国内市场,派格生物作为GLP-1赛道的重要参与者,正迎来估值重构的关键节点。Metsera值百亿,派格值多少?Metsera在超长效GLP-1技术上的潜力,也为拥有“月级给药GLP-1资产”的生物医药企业确立了百亿美元级估值的定位,未来,派格生物能否实现估值向龙头看齐,资本市场正在重新定价这一技术路径。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s/YEnal8zNjRhD5mCdRvAKiA","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"weixin_highlight","symbols":["BK4139","MTSR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514097940","title":"Metsera(MTSR.US)获坎托菲茨杰拉德公司首次覆盖,给予增持评级。","url":"https://stock-news.laohu8.com/highlight/detail?id=2514097940","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514097940?lang=zh_cn&edition=full","pubTime":"2025-02-25 22:22","pubTimestamp":1740493354,"startTime":"0","endTime":"0","summary":"Metsera(MTSR.US)获坎托菲茨杰拉德公司首次覆盖,给予增持评级。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/25222248383565.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["MTSR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2511567929","title":"热闹的“2025减肥药第一股”,不属于我们","url":"https://stock-news.laohu8.com/highlight/detail?id=2511567929","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2511567929?lang=zh_cn&edition=full","pubTime":"2025-02-13 13:54","pubTimestamp":1739426077,"startTime":"0","endTime":"0","summary":"2025年,美股第一家上市的减肥药biotech涨疯了。1月31日,Metsera上市首日,股价涨幅达到47.22%。在接下来的7个交易日里,股价继续上涨,最新市值已经突破30亿美元。而这一切,距离Metsera创立的2022年,不过3年时间。对于国内外众多押注GLP-1的biotech来说,这无疑也是他们梦寐以求的。公司的定位是“彻底改变肥胖治疗”,其核心布局分为两大类。所以,Metsera认为,MET-097i的给药周期,能延长至1个月1次。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/250698","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK1574","BK1191","BK4139","06978","01477","MTSR","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2508925197","title":"Metsera纳斯达克上市:首日大涨47%,市值28亿美元,主治肥胖症","url":"https://stock-news.laohu8.com/highlight/detail?id=2508925197","media":"雷递网","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2508925197?lang=zh_cn&edition=full","pubTime":"2025-02-01 18:26","pubTimestamp":1738405576,"startTime":"0","endTime":"0","summary":"临床阶段的生物技术公司Metsera(股票代码:“MTSR”)昨日在美国纳斯达克上市。Metsera发行价为18美元,发行1528万股,募资总额为2.75亿美元。Metsera开盘价为25.5美元,较发行价上涨41.7%;收盘价为26.5美元,较发行价上涨47%;以收盘价计算,公司市值为27.81亿美元。","market":"us","thumbnail":"https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20250201/6387403112880683398066864.jpeg","type":0,"news_type":0,"thumbnails":["https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20250201/6387403112880683398066864.jpeg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.leinews.com/n28924/detail.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"leinews_highlight","symbols":["03086","BK4007","BK1147","MNQmain","NVIW.SI","QLD",".IXIC","TSYW.SI","ARTL","TQQQ","SQQQ","MTSR","NDX","PSQ","NQmain","QID","USJW.SI","USAW.SI"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1191771744","title":"异动解读 | Metsera在纳斯达克成功上市 筹资2.75亿美元 股价盘中大涨41.67%","url":"https://stock-news.laohu8.com/highlight/detail?id=1191771744","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1191771744?lang=zh_cn&edition=full","pubTime":"2025-02-01 01:36","pubTimestamp":1738344987,"startTime":"0","endTime":"0","summary":"在医疗行业IPO活跃的大环境下,Metsera Inc. 于今日在美国纳斯达克成功上市,公司股价盘中大涨41.67%,引起了市场广泛关注。据报道,Metsera是一家临床阶段的生物技术公司,正在开发基于GLP-1机制和其他生物靶点的注射和口服药物来治疗肥胖症及相关疾病。在此次IPO中,公司以每股18美元的发行价共发行了1528万股,募资总额高达2.75亿美元。以发行价计算,Metsera的估值约为18.5亿美元。IPO后,这些机构将继续持有Metsera股权。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"异动解读 | Metsera在纳斯达克成功上市 筹资2.75亿美元 股价盘中大涨41.67%","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["MTSR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2507326479","title":"Metsera今晚纳斯达克上市:发行价18美元 募资2.75亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2507326479","media":"雷递网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2507326479?lang=zh_cn&edition=full","pubTime":"2025-01-31 16:24","pubTimestamp":1738311880,"startTime":"0","endTime":"0","summary":"临床阶段的生物技术公司Metsera(股票代码:“MTSR”)将于今日在美国纳斯达克上市,发行价为18美元,发行1528万股,募资总额为2.75亿美元。","market":"us","thumbnail":"https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20250131/6387393747620405815700744.jpeg","type":0,"news_type":0,"thumbnails":["https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20250131/6387393747620405815700744.jpeg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.leinews.com/n28921/detail.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"leinews_highlight","symbols":["USAW.SI",".IXIC","03086","NQmain","NDX","QID","SQQQ","BK4007","USJW.SI","TQQQ","NVIW.SI","BK1147","ARTL","MTSR","TSYW.SI","PSQ","QLD","MNQmain"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2507331069","title":"医疗IPO活跃,今晚Metsera和Maze上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2507331069","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2507331069?lang=zh_cn&edition=full","pubTime":"2025-01-31 15:40","pubTimestamp":1738309211,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,Metsera和Maze Therapeutics这两家制药商在周四公布了首次公开募股定价。根据一份声明,Metsera IPO定价为每股18美元,该公司将出售1530万股股票以筹资2.75亿美元。资料显示,Metsera是一家位于临床阶段的生物技术公司,开发治疗肥胖及相关疾病的注射和口服药物。该公司的最大股东是Third Rock Ventures的子公司,其他投资者包括ARCH Venture Partners的子公司等。在这个1月,Beta Bionics周三进行了2.04亿美元的IPO,亚盛医药于1月23日发行了1.26亿美元的美国存托股票。","market":"us","thumbnail":"https://static.tigerbbs.com/25bb080e73b6be662c435ea6aeaec9c7","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/25bb080e73b6be662c435ea6aeaec9c7"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1245141.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["MAZE","MTSR","159891"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.metsera.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":1.0388},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":0.0057},{"period":"1month","weight":-0.0008},{"period":"3month","weight":0.12},{"period":"6month","weight":0.088},{"period":"1year","weight":0.2286},{"period":"ytd","weight":0.0877}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Metsera, Inc.最初于2022年6月29日根据特拉华州法律注册成立。该公司是一家临床阶段的生物技术公司,开发下一代注射和口服营养刺激激素,或NUSH,类似物肽,用于治疗肥胖、超重和相关疾病。","exchange":"NASDAQ","name":"Metsera Inc.","nameEN":"Metsera Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Metsera Inc.(MTSR)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Metsera Inc.(MTSR)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Metsera Inc.,MTSR,Metsera Inc.股票,Metsera Inc.股票老虎,Metsera Inc.股票老虎国际,Metsera Inc.行情,Metsera Inc.股票行情,Metsera Inc.股价,Metsera Inc.股市,Metsera Inc.股票价格,Metsera Inc.股票交易,Metsera Inc.股票购买,Metsera Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Metsera Inc.(MTSR)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Metsera Inc.(MTSR)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}